Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
Hong Kong joins global jurisdictions in tightening cryptocurrency regulations in 2023, emphasizing the importance of consumer protection and market stability ...